GO:0019216 regulation of lipid metabolic process: Metabolic Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019216 regulation of lipid metabolic process describes any biological process that modulates the frequency, rate, or extent of the chemical reactions and pathways involving lipids.
• This regulatory term encompasses de novo lipogenesis, lipolysis, fatty acid uptake and oxidation, lipid droplet dynamics, and lipid signaling, all coordinated by enzymes, transcription factors, and E3 ubiquitin ligases.
• Dysregulation of lipid metabolism is a central driver of metabolic syndrome, hepatic and renal injury, cardiac fibrosis, and age-related diseases.
• Key regulatory nodes include SREBP1, PPARs, CD36, ATGL, HSL, and E3 ubiquitin ligases that control lipid enzyme stability.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of lipid regulatory networks in adipocytes, hepatocytes, cardiomyocytes, and other cell types.
• Understanding GO:0019216 is essential for developing therapeutics targeting obesity, non-alcoholic fatty liver disease, atherosclerosis, and metabolic cardiomyopathy.
Description
The regulation of lipid metabolic process (GO:0019216) is a fundamental biological process that governs how cells and organisms control the synthesis, breakdown, storage, and utilization of lipids. Lipids are not only structural components of membranes and energy reservoirs but also potent signaling molecules, and their metabolism must be precisely tuned to match physiological demands. This GO term captures the regulatory inputs that modulate the frequency, rate, or extent of all chemical reactions and pathways involving lipids, including de novo lipogenesis, lipolysis, fatty acid oxidation, and lipid droplet dynamics. Researchers study GO:0019216 because its dysregulation is causally linked to prevalent human diseases such as metabolic syndrome, hepatic steatosis, cardiac fibrosis, and cellular senescence. The regulatory layer includes transcription factors, kinases, ubiquitin ligases, and lipid droplet-associated proteins that respond to nutritional and hormonal cues. Understanding these mechanisms at the molecular level is a prerequisite for identifying therapeutic targets and developing precision interventions.
regulation of lipid metabolic process At A Glance
| GO ID | GO:0019216 |
|---|---|
| GO term | regulation of lipid metabolic process |
| Ontology | biological_process |
| Synonym | regulation of lipid metabolism |
| Definition | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. |
| Major function | Controls lipid synthesis, breakdown, storage, and signaling to maintain energy and membrane homeostasis. |
| Key regulatory nodes | SREBP1, PPARs, CD36, ATGL, HSL, E3 ubiquitin ligases, lipid droplet proteins. |
| Associated diseases | Metabolic syndrome, hepatic and renal injury, cardiac fibrosis, cellular senescence, obesity. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, lipidomics, RNA-seq, proteomics, imaging. |
What Is GO:0019216?
GO:0019216 regulation of lipid metabolic process is defined as any process that modulates the frequency, rate, or extent of the chemical reactions and pathways involving lipids. In practical terms, it encompasses all molecular events that adjust lipid synthesis, degradation, transport, and interconversion in response to cellular and systemic signals, without itself being the metabolic conversion of lipids.
Why Is regulation of lipid metabolic process Important in Cell Biology?
GO:0019216 is critically important because lipids are central to energy storage, membrane integrity, and signal transduction, and their dysregulation underlies some of the most prevalent human diseases. The regulatory mechanisms captured by this term determine whether fatty acids are oxidized, esterified into triglycerides, or incorporated into signaling lipids, and failures in this control contribute to insulin resistance, steatohepatitis, cardiomyopathy, and accelerated aging. Moreover, lipid metabolism reprogramming is increasingly recognized as a hallmark of cancer and fibrosis, making this GO term a high-value target for both mechanistic research and therapeutic development.
• Controls energy homeostasis by balancing de novo lipogenesis and lipolysis in adipose tissue.
• Regulates fatty acid uptake and oxidation in heart and muscle via CD36 and mitochondrial contacts.
• Dysregulation causes hepatic steatosis and renal injury in metabolic syndrome.
• Lipid metabolism reprogramming drives cardiac fibrosis and heart failure.
• Altered lipid regulation contributes to cellular senescence and age-related diseases.
• E3 ubiquitin ligases provide post-translational control of lipid enzymes and are emerging drug targets.
• Lipid droplet-mitochondria contacts coordinate lipid storage with oxidative capacity.
• Provides mechanistic biomarkers for metabolic disease diagnosis and progression.
• Enables CRISPR-based functional genomics to identify causal lipid regulators.
• Supports development of precision therapeutics for obesity, NAFLD, and atherosclerosis.
What Happens During regulation of lipid metabolic process?
De Novo Lipogenesis and Its Transcriptional Control
In simple terms: Cells build new fat molecules from non-fat precursors, and this building process is switched on or off by specific transcription factors.
De novo lipogenesis (DNL) converts carbohydrates and amino acids into fatty acids, primarily in liver and adipose tissue. This pathway is regulated by transcription factors such as SREBP1c and ChREBP, which respond to insulin and glucose signals to activate lipogenic enzymes including ACC, FASN, and SCD1. The regulation of DNL is critical for maintaining energy balance, and its overactivation contributes to hypertriglyceridemia and hepatic steatosis.
Lipolysis and Fatty Acid Mobilization
In simple terms: Stored fat is broken down and released as free fatty acids when the body needs energy.
Lipolysis is the regulated hydrolysis of triglycerides into glycerol and free fatty acids, mediated by lipases such as ATGL, HSL, and MGL. This process is controlled by hormonal signals (catecholamines, insulin) and by access of lipases to lipid droplets, which is gated by perilipin proteins. Dysregulated lipolysis contributes to elevated circulating fatty acids and ectopic lipid accumulation in metabolic syndrome.
Fatty Acid Uptake and Mitochondrial Oxidation
In simple terms: Cells take up fatty acids from the blood and burn them in mitochondria for energy, and this uptake and burning are tightly regulated.
CD36 facilitates fatty acid uptake across the plasma membrane, and its surface availability is regulated by trafficking and post-translational modifications. Once inside, fatty acids are activated to acyl-CoAs and transported into mitochondria via CPT1 for beta-oxidation. The coordination between uptake and oxidation is essential to prevent lipotoxicity, and CD36 is a therapeutic target in metabolic disease.
Lipid Droplet Dynamics and Organelle Contacts
In simple terms: Fat is stored in droplets that communicate with other cell structures to manage energy and signaling.
Lipid droplets (LDs) are dynamic organelles that store neutral lipids and interact with mitochondria, ER, and peroxisomes. LD-mitochondria contacts facilitate fatty acid transfer for oxidation and are regulated by proteins such as PLIN5 and MIGA2. These contacts are critical for matching lipid storage with metabolic demand, and their disruption is linked to metabolic disease.
Post-Translational Control by Ubiquitin Ligases
In simple terms: Cells tag lipid enzymes with ubiquitin to control their stability and activity.
E3 ubiquitin ligases regulate the abundance of key lipid metabolic enzymes and regulatory proteins through ubiquitination and proteasomal degradation. This layer of regulation allows rapid adaptation to changing metabolic conditions and is implicated in lipid-associated metabolic diseases, offering new targets for intervention.
Key Genes Involved in GO:0019216 regulation of lipid metabolic process
The following genes and proteins are central regulators of lipid metabolic processes, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBP1 | Master transcription factor for de novo lipogenesis | Target for hepatic steatosis and insulin resistance |
| PPARG | Adipocyte differentiation and lipid storage regulator | Thiazolidinedione target in diabetes |
| CD36 | Fatty acid uptake transporter | Therapeutic target in metabolic and cardiac disease |
| ATGL (PNPLA2) | Rate-limiting triglyceride lipase | Lipolysis regulation and neutral lipid storage disease |
| HSL (LIPE) | Hormone-sensitive lipase for diacylglycerol hydrolysis | Lipolysis control in adipocytes |
| PLIN1 | Lipid droplet coat protein regulating lipase access | Lipolysis and lipodystrophy |
| PLIN5 | LD-mitochondria contact regulator | Fatty acid oxidation in heart and liver |
| CPT1A | Mitochondrial fatty acid import | Beta-oxidation regulation |
| FASN | Fatty acid synthase | De novo lipogenesis and cancer metabolism |
| ACC1 (ACACA) | Acetyl-CoA carboxylase for malonyl-CoA | Lipogenesis regulation |
| SCD1 | Stearoyl-CoA desaturase for monounsaturated fatty acids | Lipid composition and metabolic disease |
| ChREBP (MLXIPL) | Glucose-responsive lipogenic transcription factor | Carbohydrate-driven lipogenesis |
| UBE3A | E3 ubiquitin ligase | Lipid metabolism regulation |
| FBXW7 | E3 ubiquitin ligase | Lipid enzyme degradation |
| MARCH5 | Mitochondrial E3 ligase | LD-mitochondria contacts |
| MIGA2 | ER-mitochondria tethering protein | LD-mitochondria contacts |
| DGAT1 | Diacylglycerol acyltransferase for TG synthesis | Lipid storage and metabolic disease |
How Is regulation of lipid metabolic process Regulated?
The regulation of lipid metabolic process is controlled at multiple levels. Transcriptional regulation by SREBP1c, PPARs, and ChREBP responds to nutritional and hormonal signals. Post-translational control by E3 ubiquitin ligases modulates the stability of lipogenic and lipolytic enzymes. Hormonal signals such as insulin and catecholamines acutely regulate lipolysis and lipogenesis. Additionally, lipid droplet-associated proteins and organelle contact sites provide spatial regulation of lipid flux. This multilayered regulation ensures metabolic flexibility and is disrupted in metabolic syndrome and related diseases.
regulation of lipid metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SREBP1 | Hepatic steatosis, insulin resistance | Liver-specific KO or overexpression in mice |
| CD36 | Cardiac lipid overload, cardiomyopathy | Cardiomyocyte-specific KO or point mutation |
| ATGL | Neutral lipid storage disease | Adipocyte KO and knock-in of patient mutations |
| PLIN5 | Cardiac steatosis and lipotoxicity | Knockout and tagged knock-in for imaging |
| FBXW7 | Lipid-associated metabolic disease | CRISPR KO in hepatocytes and adipocytes |
Metabolic Syndrome and Hepatic/Renal Injury
Dysregulation of lipid metabolism is a core feature of metabolic syndrome, contributing to hepatic steatosis, inflammation, and renal injury. Mechanisms include increased de novo lipogenesis, impaired fatty acid oxidation, and lipotoxicity in hepatocytes and renal tubular cells. These processes are driven by transcription factors such as SREBP1 and inflammatory signaling, and they represent targets for therapeutic intervention.
Cardiac Fibrosis and Cardiomyopathy
Lipid metabolism reprogramming in cardiac fibroblasts and cardiomyocytes contributes to cardiac fibrosis and heart failure. Altered fatty acid uptake via CD36 and changes in lipid droplet dynamics promote fibrotic remodeling. Targeting lipid metabolic pathways may attenuate fibrosis and improve cardiac function.
Cellular Senescence and Age-Related Diseases
Lipid metabolism is reprogrammed during cellular senescence, with accumulation of specific lipid species that reinforce the senescence-associated secretory phenotype. This link positions lipid regulatory enzymes as emerging targets for age-related diseases.
Lipid-Associated Metabolic Diseases and E3 Ligases
E3 ubiquitin ligases that control lipid enzyme stability are implicated in obesity, diabetes, and fatty liver disease. Their dysregulation leads to aberrant lipid accumulation and metabolic dysfunction, making them attractive drug targets.
From regulation of lipid metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for lipogenesis? | CRISPR knockout in hepatocytes or adipocytes |
| Does a specific point mutation alter enzyme activity? | CRISPR point mutation knock-in |
| How does a regulatory protein localize to lipid droplets? | Tagged knock-in (e.g., GFP) and imaging |
| Does overexpression of a lipogenic factor drive steatosis? | CRISPR overexpression or cDNA overexpression |
| Which genes regulate lipid metabolism in a genome-wide manner? | CRISPR library screening with lipid readouts |
| What are the downstream pathways of a lipid regulator? | RNA-seq and proteomics after KO or overexpression |
How to Study the regulation of lipid metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR KO | Gene function loss | Test requirement of a lipid regulator |
| CRISPR point mutation | Specific amino acid function | Dissect enzyme catalytic or regulatory sites |
| CRISPR knock-in | Tagged or reporter protein | Localization and interaction studies |
| CRISPR overexpression | Gain-of-function | Drive lipogenesis or lipid storage |
| Lipidomics | Lipid species abundance | Quantify changes in lipid composition |
| RNA-seq | Transcriptome changes | Identify downstream pathways |
| Proteomics | Protein abundance and modifications | Detect ubiquitination and stability changes |
| Imaging | Subcellular localization | Visualize lipid droplets and contacts |
CRISPR Functional Genomics
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of lipid regulatory genes. Pooled CRISPR screens with lipid staining or lipidomic readouts can identify novel regulators of GO:0019216.
Lipidomics and Metabolomics
Mass spectrometry-based lipidomics quantifies hundreds of lipid species to reveal how genetic perturbations alter lipid composition and flux, providing mechanistic insight into regulatory nodes.
Transcriptomics and Proteomics
RNA-seq and proteomics measure changes in gene and protein expression after manipulating candidate regulators, uncovering transcriptional and post-translational networks.
Imaging and Organelle Contact Analysis
Fluorescence microscopy and proximity ligation assays visualize lipid droplets, mitochondria, and their contacts, revealing spatial regulation of lipid metabolism.
How CRISPR Can Be Used to Study GO:0019216 regulation of lipid metabolic process
Knockout
CRISPR knockout of candidate genes such as SREBP1, CD36, or ATGL in cell models (hepatocytes, adipocytes, cardiomyocytes) can determine whether they are required for specific lipid metabolic processes. This approach is foundational for causal inference in GO:0019216 research.
Point Mutation
Point mutation knock-in allows precise testing of phosphorylation sites, catalytic residues, or disease-associated variants in lipid enzymes. For example, mutating lipase catalytic residues clarifies their role in lipolysis.
Knock-in
Tagged knock-in (e.g., GFP, HA, or proximity labeling tags) enables visualization and interactome analysis of lipid regulatory proteins at endogenous expression levels, revealing dynamic localization to lipid droplets and mitochondria.
Overexpression
CRISPR activation or cDNA overexpression of lipogenic transcription factors such as SREBP1c can drive lipid accumulation and model steatosis, providing gain-of-function evidence for regulatory mechanisms.
How EDITGENE Supports regulation of lipid metabolic process Research
Researchers studying regulation of lipid metabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid homeostasis, and CRISPR-based models provide the most direct route to such causal evidence. EDITGENE offers a comprehensive suite of services to generate and characterize these models.
Contact EDITGENE today to design your custom CRISPR model for regulation of lipid metabolic process research.
Frequently Asked Questions About regulation of lipid metabolic process
What is GO:0019216 regulation of lipid metabolic process?
GO:0019216 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate, or extent of the chemical reactions and pathways involving lipids.
What genes are involved in regulation of lipid metabolic process?
Key genes include SREBP1, PPARG, CD36, ATGL, HSL, PLIN1, PLIN5, CPT1A, FASN, ACC1, SCD1, ChREBP, and various E3 ubiquitin ligases such as FBXW7.
How is lipid metabolism regulated in cells?
Lipid metabolism is regulated at transcriptional, post-translational, and spatial levels by transcription factors, ubiquitin ligases, hormones, and lipid droplet-associated proteins.
What diseases are associated with dysregulated lipid metabolism?
Dysregulated lipid metabolism is associated with metabolic syndrome, hepatic and renal injury, cardiac fibrosis, cellular senescence, obesity, and diabetes.
What is the role of CD36 in lipid metabolism?
CD36 is a fatty acid transporter that regulates cellular fatty acid uptake and is a therapeutic target for metabolic and cardiac diseases.
How do E3 ubiquitin ligases regulate lipid metabolism?
E3 ubiquitin ligases control the stability and activity of lipid metabolic enzymes through ubiquitination, thereby regulating lipid homeostasis.
What are lipid droplet-mitochondria contacts?
These are physical connections between lipid droplets and mitochondria that facilitate fatty acid transfer for oxidation and are regulated by proteins such as PLIN5 and MIGA2.
How can CRISPR be used to study lipid metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of genes in lipid metabolic pathways, while CRISPR screens identify novel regulators.
What methods are used to study regulation of lipid metabolic process?
Common methods include lipidomics, RNA-seq, proteomics, imaging, and CRISPR functional genomics.
Why is regulation of lipid metabolic process important for drug discovery?
Because its dysregulation drives major diseases, targeting lipid regulatory nodes offers therapeutic opportunities for metabolic and age-related diseases.
Conclusion
GO:0019216 regulation of lipid metabolic process is a central biological process that controls lipid synthesis, breakdown, storage, and signaling. Its dysregulation is implicated in metabolic syndrome, cardiac fibrosis, cellular senescence, and other prevalent diseases. Advances in CRISPR-based models and multi-omics are accelerating the discovery of causal regulators and therapeutic targets. EDITGENE provides end-to-end services to support this research and translate findings into clinical impact.
References
- 1. Song Z et al.. 2018. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues.. Nutrients 10(10) PMID: 30274245
- 2. Zou Y et al.. 2024. Regulation of lipid metabolism by E3 ubiquitin ligases in lipid-associated metabolic diseases.. Int J Biol Macromol 265(Pt 2):130961 PMID: 38508558
- 3. Rong J et al.. 2024. Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome.. Int J Biol Sci 20(12):4783-4798 PMID: 39309427
- 4. Cho CH et al.. 2023. Adipose tissue lipid metabolism: lipolysis.. Curr Opin Genet Dev 83:102114 PMID: 37738733
- 5. Glatz JFC et al.. 2024. CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease.. Physiol Rev 104(2):727-764 PMID: 37882731
- 6. Fan H et al.. 2024. Lipid Droplet-Mitochondria Contacts in Health and Disease.. Int J Mol Sci 25(13) PMID: 38999988
- 7. Zeng Q et al.. 2024. Lipids and lipid metabolism in cellular senescence: Emerging targets for age-related diseases.. Ageing Res Rev 97:102294 PMID: 38583577
- 8. Lin LC et al.. 2024. Lipid metabolism reprogramming in cardiac fibrosis.. Trends Endocrinol Metab 35(2):164-175 PMID: 37949734
